ADMP Adamis Pharmaceuticals Corporat

3.50
+0  (0%)
Previous Close 3.50
Open 3.50
Price To book 2.95
Market Cap 75.54M
Shares 21,584,000
Volume 208,051
Short Ratio 7.00
Av. Daily Volume 256,135

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued March 27 2015. CRL issued again June 6, 2016. NDA resubmission announced December 16, 2016. NDA acceptance announced January 19, 2017. No PDUFA date announced. PDUFA date estimate June 15, 2017 using 6-month time frame from resubmission.
Epinephrine Pre-filled Syringe (PFS)
Emergency treatment of anaphylaxis.
Phase 3 IND to be submitted 1H 2017.
APC-3000
Allergic Rhinitis
Phase 3 planned
APC-1000
Asthma/COPD

Latest News

  1. Adamis Pharmaceuticals Announces FDA Acceptance of Resubmission of Its Epinephrine Pre-Filled Syringe NDA
  2. ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
  3. ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Other Events
  4. These 5 Stocks Under $10 Could Make You a Lot of Money
  5. Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA
  6. Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA
  7. Is VOXX International Corp (VOXX) A Good Stock To Buy?
  8. ADAMIS PHARMACEUTICALS CORP Financials
  9. ADAMIS PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report
  10. ADAMIS PHARMACEUTICALS CORP Files SEC form 8-K, Financial Statements and Exhibits
  11. Relief From EpiPen's Stranglehold May Come From Rivals Before Politicians
  12. Here's a Reason Why Adamis Pharmaceuticals (ADMP) Stock Is Slumping Today
  13. 8 Top Movers and Hot Stocks for Monday
  14. Here's a Reason Why Adamis Pharmaceuticals (ADMP) Stock Is Soaring Today
  15. Mylan Is Done Leaning on EpiPen Sales and That Could be a Big Problem
  16. 5 Breakout Stocks Under $10 Set to Soar
  17. ADAMIS PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report
  18. Adamis Pharmaceuticals Strengthens Patent Portfolio for its Dry Powder Inhaler